Vascular endothelial growth factor a in intraocular vascular disease - PubMed (original) (raw)
Review
. 2013 Jan;120(1):106-14.
doi: 10.1016/j.ophtha.2012.07.038. Epub 2012 Sep 29.
Affiliations
- PMID: 23031671
- DOI: 10.1016/j.ophtha.2012.07.038
Review
Vascular endothelial growth factor a in intraocular vascular disease
Joan W Miller et al. Ophthalmology. 2013 Jan.
Abstract
The vascular beds supplying the retina may sustain injury as a result of underlying disease such as diabetes, and/or the interaction of genetic predisposition, environmental insults, and age. The vascular pathologic features observed in different intraocular vascular diseases can be categorized broadly as proliferation, exemplified by proliferative diabetic retinopathy, leakage such as macular edema secondary to retinal vein occlusion, or a combination of proliferation and leakage, as seen in neovascular age-related macular degeneration (AMD). The World Health Organization has identified diabetic retinopathy and AMD as priority eye diseases for the prevention of vision loss in developed countries. The pathologic transformations of the retinal vasculature seen in intraocular vascular disease are associated with increased expression of vascular endothelial growth factor A (VEGF), a potent endothelial-specific mitogen. Furthermore, in model systems, VEGF alone is sufficient to trigger intraocular neovascularization, and its inhibition is associated with functional and anatomic improvements in the affected eye. Therapeutic interventions with effect on VEGF include intraocular capture and neutralization by engineered antibodies or chimeric receptors, downregulation of its expression with steroids, or alleviation of retinal ischemia, a major stimulus for VEGF expression, with retinal ablation by laser treatment. Data from prospective randomized clinical trials indicate that VEGF inhibition is a potent therapeutic strategy for intraocular vascular disease. These findings are changing clinical practice and are stimuli for further study of the basic mechanisms controlling intraocular angiogenesis.
Financial disclosure(s): Proprietary or commercial disclosure may be found after the references.
Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Similar articles
- Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. Amin RH, et al. Invest Ophthalmol Vis Sci. 1997 Jan;38(1):36-47. Invest Ophthalmol Vis Sci. 1997. PMID: 9008628 - [Aging and retinal vascular diseases].
Takagi H. Takagi H. Nippon Ganka Gakkai Zasshi. 2007 Mar;111(3):207-30; discussion 231. Nippon Ganka Gakkai Zasshi. 2007. PMID: 17402563 Review. Japanese. - Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.
Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Pe'er J, et al. Lab Invest. 1995 Jun;72(6):638-45. Lab Invest. 1995. PMID: 7540233 - Role of vascular endothelial growth factor in ocular angiogenesis.
Shams N, Ianchulev T. Shams N, et al. Ophthalmol Clin North Am. 2006 Sep;19(3):335-44. doi: 10.1016/j.ohc.2006.05.005. Ophthalmol Clin North Am. 2006. PMID: 16935208 Review. - Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Aiello LP, et al. N Engl J Med. 1994 Dec 1;331(22):1480-7. doi: 10.1056/NEJM199412013312203. N Engl J Med. 1994. PMID: 7526212
Cited by
- Genetic polymorphisms of vascular endothelial growth factor and risk for retinopathy of prematurity in South of Iran.
Kalmeh ZA, Azarpira N, Mosallaei M, Hosseini H, Malekpour Z. Kalmeh ZA, et al. Mol Biol Rep. 2013 Jul;40(7):4613-8. doi: 10.1007/s11033-013-2554-y. Epub 2013 May 4. Mol Biol Rep. 2013. PMID: 23644986 - Correlation between ELF-PEMF exposure and Human RPE Cell Proliferation, Apoptosis and Gene Expression.
Oladnabi M, Mishan MA, Rezaeikanavi M, Zargari M, Sadeghi RN, Bagheri A. Oladnabi M, et al. J Ophthalmic Vis Res. 2021 Apr 29;16(2):202-211. doi: 10.18502/jovr.v16i2.9084. eCollection 2021 Apr-Jun. J Ophthalmic Vis Res. 2021. PMID: 34055258 Free PMC article. - Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab.
Nudleman E, Wolfe JD, Woodward MA, Yonekawa Y, Williams GA, Hassan TS. Nudleman E, et al. Clin Ophthalmol. 2016 Jun 8;10:1053-7. doi: 10.2147/OPTH.S109894. eCollection 2016. Clin Ophthalmol. 2016. PMID: 27354759 Free PMC article. - Intravitreal Injection of Conbercept Combined with Dexamethasone for Macular Edema Following Central Retinal Vein Occlusion.
Wu P, Zhang P, Xu J, Ma W, Li L, Xu H. Wu P, et al. Clin Ophthalmol. 2024 Jun 26;18:1851-1860. doi: 10.2147/OPTH.S448671. eCollection 2024. Clin Ophthalmol. 2024. PMID: 38948340 Free PMC article. - Anti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1.
Joe SG, Yoon YH, Choi JA, Koh JY. Joe SG, et al. PLoS One. 2015 Mar 18;10(3):e0119708. doi: 10.1371/journal.pone.0119708. eCollection 2015. PLoS One. 2015. PMID: 25785990 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical